FDA Approves Roche's Tecentriq for Adjuvant Treatment of Stage III Colon Cancer

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with fluoropyrimidine and oxaliplatin for the adjuvant treatment of a specific type of Stage III colon cancer. This approval is based on results from the landmark Phase III ATOMIC study.